Drug Trial Radar · NCT07185282
A Phase 3 Study of MH004 Ointment in Patients With Mild to Moderate Atopic Dermatitis
Last checked: Nov 19, 2026Latest source record: Sep 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
375
Actual
Start
Jun 10, 2023
Primary completion
Dec 13, 2024
Study completion Aug 15, 2025
Sponsor
- Lead sponsor
- Minghui Pharmaceutical (Hangzhou) LtdIndustry
- Sponsor type
- Industry
- First posted
- Sep 22, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, randomized, double-blind, vehicle-controlled phase III study of MH004 Ointment with a 44-week open-label long-term safety extension period. The study was designed to evaluate the safety, tolerability, pharmacokinetics (PK), and primary efficacy of MH004 Ointment in adolescents and adults with mild to moderate atopic dermatitis.
Conditions
- Atopic Dermatitis (AD)
Interventions
MH004 OintmentDrug
MH004 1% ointment applied topically to the affected area as a thin film twice daily.
Vehicle OintmentDrug
Matching vehicle ointment applied topically to the affected area as a thin film twice daily.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of participants achieving Investigator's Global Assessment treatment success (IGA-TS) at Week 4.Time frame: Baseline to week 4.
- Proportion of participants achieving EASI-75 at Week 4.Time frame: Baseline to week 4.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Peking University People's Hospital
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.